Sign in

CIK 0001477845 · Non-accelerated filer<br>Smaller reporting company

Annovis Bio, Inc.

Sign in to watch
Ticker
ANVS
Exchange
NYSE
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
262540421
Phone
484-875-3192
Business address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA, 19355
Former names
QR Pharma, Inc.
  1. 4 Open-market buy Director bought 5,000,000 shares at $1.00 ($5,000,000)
  2. 4 Open-market buy Director bought 76,344 shares at an average $1.87 ($142,779)
  3. 4 Open-market buy Director bought 713,800 shares at $2.10 ($1,498,980)
  4. 4 Open-market buy Director bought 45,000 shares at an average $4.31 ($193,794)
  5. 4/A Open-market buy Director bought 39,200 shares at an average $4.08 ($159,886)
  6. 4 Open-market buy Director bought 39,200 shares at an average $4.08 ($159,886)
  7. 4 Open-market buy Director bought 20,000 shares at an average $3.50 ($69,900)
  8. 4 Open-market buy Director bought 15,000 shares at $2.11 ($31,650)
  9. 4 Open-market buy President & CEO bought 97,561 shares at $2.05 ($200,000)
  10. 4 Open-market buy Director bought 975,610 shares at $2.05 ($2,000,001)
  11. 4 Option exercise Director acquired 7,142 shares (option exercise)
  12. 4 Grant or award Director acquired 15,000 shares (grant or award)
  13. 4 Grant or award Director acquired 18,645 shares (grant or award)
  14. 4 Grant or award Vice President, Finance acquired 500 shares (grant or award)
  15. 4 Grant or award Director acquired 25,001 shares (grant or award)
  16. 4 Grant or award Director acquired 2,000 shares (grant or award)
  17. 4 Grant or award President & CEO acquired 46,000 shares (grant or award)
  18. 4 Grant or award Director acquired 5,000 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Derivatives Options or other derivatives

Page 1 of 5 · 91 filings